Federal Budget 2026: Pharma / Medtech Stakeholder Brief

Executive Summary

1. None of the Pharmaceutical and Life Sciences Sector Task Force's 39 recommendations carries a dollar amount in this budget, so the medicines policy that matters most to this client is still to come.
2. After the Productivity Mega Deduction, the tax rate on new manufacturing investment is -1.2% in Canada against 11.1% in the United States, a gap of 12.3 percentage points (calculated) that favours building production lines here (Budget 2026: Masters of Our Destiny, Chapter 1, Chart 1.1).
3. About 73% of the Canada Growth Incentive's $715 million cost falls in 2030-31 (calculated), because the shares must be held for 36 months before the exemption applies.

Top 5 Relevant Budget Measures

SR&ED commercialisation expansion. Tests, technological validations and studies needed to meet regulatory requirements for initial approval now qualify, if directly related to an eligible SR&ED project (Tax Measures: Supplementary Information, Business Income Tax Measures). So do patent and certificate of supplementary protection costs, in Canada or abroad. The chapter table books $936 million over five years, with $25 million in 2026-27. For a drug or device developer, the study work behind a Health Canada submission is often the costliest stage before revenue. The budget does not say whether a clinical trial counts as a study "to meet regulatory requirements," and the CRA's sector guidance will decide that.

Productivity Mega Deduction. The deduction costs $36,055 million over five years and was announced September 15, 2026. Chapter 1 lists medical imaging, laboratory analysers and sterilisation equipment among eligible assets. Long-lived buildings and certain intangibles are excluded, so plant shells and acquired licences do not qualify. For a manufacturer choosing between a Canadian and a U.S. site, the equipment cost of a fill-finish line or a device plant is now written off in year one.

Canada Growth Incentive. The exemption covers up to $15 million of gains on shares of a Canadian-controlled private corporation with assets of $100 million or less, held at least 36 months (Tax Measures: Supplementary Information, Personal Income Tax Measures). Professional practices of physicians and other health care practitioners are excluded. Product companies in biotech and devices are not. The chapter table books $525 million of the $715 million in 2030-31.

Strategic Response Fund. The fund gets $1 billion over six years from 2028-29, with bio-manufacturing named among target areas (Budget 2026: Masters of Our Destiny, Chapter 1, s. 1.1). Nothing arrives inside the first two years of the horizon. This suggests new large-project contribution agreements for life sciences will be scarce until 2028-29.

Task Force response. The ministers of Health and Industry published the report in June 2026. The budget says details "will be announced in the coming months." The only related money is $10 million over two years for the Praxis Spinal Cord Institute.

Asked For vs. Delivered

6 asks: 3 delivered 2 partly 1 not in this budget

Raise the capital gains exemption for founders and investors to $15 million

Patrick Searle, CCI, and Benjamin Bergen, CVCA, BNN Bloomberg, Oct 6

Up to $15 million per individual per business.

Canada Growth Incentive

Delivered

Let sellers reinvest proceeds in Canadian firms with tax deferred

Patrick Searle, CCI, and Benjamin Bergen, CVCA, BNN Bloomberg, Oct 6, and Daniel Perry, CCI, CBC News Network, Nov 2

The rollover window and asset test are loosened from 2027.

Canada Growth Incentive

Delivered

Build a national patent pool for Canadian firms

Vass Bednar, Canadian Shield Institute, BNN Bloomberg, Oct 29

SR&ED pays patent costs, with no patent pool.

IP policies

Partly

Pass Bill S-5 for national health data sharing

CMA, Hill Times, Nov 2

The budget does not mention the bill.

—

Not in this budget

Resource the tariff remission program so applications move faster

CME, FINA, Oct 6

Finance says it is adding resources, with no amount.

Tariff supports

Partly

Attract foreign capital and keep investment in Canada

KPMG survey, release, Oct 15

Invest in Canada gets $181.4 million over four years to court global investors, and the Mega Deduction lowers tax on new investment.

Productivity Mega Deduction

Delivered

Asks compiled by Stephen Taylor's AI Public Affairs Toolset, September 15 to November 5, 2026.

The venture and innovator groups that share this client's financing needs got both of their tax asks. The health-specific asks, on data sharing and on medicines policy, now wait on the task force response and on Parliament.

Risks

Medicines policy is undecided. The 39 recommendations cover access to medicines and industry competitiveness, and the budget commits to none of them. It does not mention pharmacare. Companies planning Canadian launches or clinical programs for 2027 cannot yet see the access and pricing rules those plans will meet.

Recapture on IP sales. If a company disposes of IP that received SR&ED support for protection costs, recapture rules apply to the related deduction and credit (Tax Measures: Supplementary Information). Many Canadian biotechs exit by selling or licensing their lead asset to a larger foreign firm. The budget does not say whether an exclusive licence counts as a disposition.

Late industrial money. The Strategic Response Fund recapitalisation starts in 2028-29. The horizontal review of business innovation programs is also running, and the government still has an average of $1.8 billion a year of savings to identify from 2028-29 to 2030-31 (Budget 2026: Masters of Our Destiny, Chapter 6). If the review consolidates innovation programs, life sciences contributions could shrink before the new fund money arrives.

Trade exposure. The budget lists almost $44 billion in support for tariff-affected workers and businesses since March 2025 and says nothing specific to pharmaceuticals or devices. The private sector average puts the dollar at 72.4 U.S. cents in 2027 (Budget 2026: Masters of Our Destiny, Annex 1, Table A1.2). Exporters gain from that rate, and importers of U.S. inputs pay more.

Opportunities

SR&ED for approval work. Wages, materials, contracts, overhead and equipment spent on regulatory studies tied to an eligible project qualify for taxation years beginning on or after November 5, 2026. Certain small and medium-sized corporations earn the enhanced 35% credit, and others the 15% general rate. The CRA will issue guidance by sector.

Immediate expensing. The Productivity Mega Deduction is permanent and covers the equipment categories the budget lists for health care and laboratories. Legislative proposals were released September 15, 2026.

GST/HST zero-rating for a cancer device. Devices specially designed for alternating electric field therapy for people with cancer are zero-rated on supplies made after November 5, 2026. The measure costs $199 million over five years, together with the massage therapy exemption. It shows Finance will add specific devices to the zero-rated list when Health Canada has approved them.

Easier medical expense claims. From the 2026 taxation year, insulin, CPAP machines, diabetes infusion pumps and blood coagulation monitors no longer need a prescription for the Medical Expense Tax Credit. For 17 other items, a practitioner's certification replaces the prescription. Device makers selling direct to patients face fewer paperwork barriers.

Tariff remission. Goods used by identified public health entities qualify for remission automatically under the United States Surtax Remission Order (2025) (Budget 2026: Masters of Our Destiny, Chapter 2, s. 2.3). Other importers can apply to the Department of Finance for individual remission.

Likely Government Intent

The government's industrial argument is about tax on capital. It says the Productivity Mega Deduction cuts the marginal effective tax rate on new business investment from 13% to 6.4%, "the lowest in the G7 and less than half the rate in the United States" (Budget 2026: Masters of Our Destiny, Chapter 1, s. 1.1). The SR&ED change follows the same logic and pays for steps between invention and sale.

On medicines, the government is keeping its options open. The task force was a joint Health and Industry effort, and the budget leaves the choices between access, price and investment for a later announcement. The Cutting Red Tape for All Canadians Act and a new rule that regulators cut $2 of burden for every $1 they add point to a regulatory agenda that may reach Health Canada. The budget does not name Health Canada's drug or device rules among the targets.

Open Questions

1. When does the task force response come, and does it carry money? Health Canada and Innovation, Science and Economic Development Canada hold it. Launch sequencing and Canadian manufacturing decisions depend on it.
2. Do clinical trials count as regulatory studies for SR&ED? The CRA's sector guidance will answer it. Trials are the largest pre-approval cost for drug developers.
3. Does an exclusive licence trigger SR&ED recapture? Finance and the CRA will settle it in draft legislation. The answer changes the value of the credit for companies that partner with large firms.
4. How much of the Strategic Response Fund goes to life sciences? Innovation, Science and Economic Development Canada sets the priorities. The budget names bio-manufacturing without a share.
5. Will Health Canada regulations fall under the red tape directive? The Treasury Board of Canada Secretariat and Health Canada hold the answer. Approval timelines and fees for drugs and devices depend on it.

Key Dates

Suggested Message Frames

For government. The budget cuts the tax rate on new manufacturing investment to -1.2%, against 11.1% in the United States (Chart 1.1). Life sciences plants are the investment that rate was built to attract.

For members and investors. The $936 million SR&ED expansion treats regulatory approval as part of innovation. The 39 task force recommendations decide whether approved products reach Canadian patients.

For media. The Canada Growth Incentive books $525 million of its $715 million cost in 2030-31. Biotech founders need the rules in law now to raise money against them.

Opposition and Media Narratives to Anticipate

The Official Opposition will focus on the $62.3 billion deficit for 2026-27 and public debt charges that rise from $60.2 billion to $85.5 billion by 2030-31 (Budget 2026: Masters of Our Destiny, Annex 1). Tax measures for business are easier for the Conservatives to support than new programs, so the SR&ED and Growth Incentive changes are unlikely targets.

The NDP and labour groups will frame the $36,055 million Productivity Mega Deduction as a corporate concession. The Registered Nurses' Association of Ontario asked before the budget for health to come ahead of corporate concessions. The Canadian Tax Observatory asked Finance to show whether the deduction produces investment that would not have happened anyway. The budget prints model estimates of higher capital stock and no such baseline, which gives critics an opening.

The Parliamentary Budget Officer is likely to examine how the operating balance counts $16.8 billion of forgone revenue from capital tax incentives in 2027-28 (Budget 2026: Masters of Our Destiny, Annex 1, Table A1.6). Health reporters and patient groups will note that the task force recommendations and pharmacare are both missing. Provinces will focus on the Canada Health Transfer floor, which falls to 3% after 2027-28 and drives their drug plan budgets.

Data Points to Monitor

• CRA SR&ED guidance. The sector guidance on commercialisation expenses decides how much of the $936 million reaches life sciences.
• Task force response. Watch for announcements from the ministers of Health and Industry and any money attached.
• Exchange rate and U.S. growth. The private sector average has the dollar at 72.4 U.S. cents and U.S. real growth at 2.2% in 2027 (Annex 1, Table A1.2).
• Ten-year bond yield. Forecast at 3.8% in 2027, which sets the cost of capital for plant investment (Annex 1, Table A1.2).
• Main Estimates for 2028-29. The first Strategic Response Fund vote under the recapitalisation.
• Horizontal review results. Promised in future publications, likely the Spring Economic Update 2027.
• Draft legislation. The Notice of Ways and Means Motion has only a general clause for SR&ED, so detailed draft text is still to come.